Peps
What is Teduglutide?
Teduglutide is a peptide medicine for short bowel syndrome with dependence on intravenous nutrition or fluids. It acts in a different pathway from GLP-1 medicines.
Biological role or research focus
GLP-2-related intestinal absorption.
Its short bowel syndrome context is different from GLP-1 appetite medicines.
Role reference: MedlinePlus · Teduglutide ↗
Names you may encounter
Gattex
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- GLP-2 analogue
- Main research area
- Intestinal absorption in short bowel syndrome
- Evidence featured
- Human randomized trial
- Source check
- October 4, 2026
Source: MedlinePlus · Teduglutide ↗
Molecular structure
Mechanism & research rationale
It promotes intestinal absorptive capacity. The key clinical question is whether patients can safely reduce the amount or frequency of parenteral support.
Source: MedlinePlus · Teduglutide ↗
Clinical uses & product context
Its medication reference describes short bowel syndrome requiring supplemental IV support. The study below evaluates a reduction in that support, not general gut comfort or weight loss.
Source: MedlinePlus · Teduglutide ↗
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2012
STEPS
Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure.
- Population / model
- 86 patients with short bowel syndrome and intestinal failure requiring parenteral support.
- Study design
- Twenty-four-week placebo-controlled study with protocol-guided support reductions.
- Main finding
- A reduction of more than 20% in support volume at weeks 20 and 24 occurred in 63% versus 30%. Mean weekly volume reduction was 4.4 versus 2.3 liters.
- Limits & context
- A response did not necessarily mean complete independence from IV support. The outcome is specific to intestinal failure, not general gut symptoms or appetite control.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Definition, classification, and causes of short bowel syndrome. ↗
Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2023 May · Journal Article, Review
Understanding short bowel syndrome: Current status and future perspectives. ↗
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2020 Mar · Journal Article, Review
Updates in Intestinal Failure Management. ↗
Journal of clinical medicine · 2025 Apr 28 · Journal Article, Review
Read available full text ↗
Teduglutide. ↗
· 2006 · Review
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
Key precautions
Intestinal polyps or malignancy history, obstruction symptoms, fluid overload, and gallbladder or pancreatic problems affect monitoring. Better absorption can also change exposure to oral medicines.
Source: MedlinePlus · Teduglutide ↗
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
0 matching video records · 0 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
No matching video has been identified in the current snapshot.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Which indication and formulation does the source describe?
- Does the video make a broader claim than the source supports?
- Its short bowel syndrome context is different from GLP-1 appetite medicines.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Does a trial response mean patients no longer needed IV support?
Not necessarily. The response threshold was a reduction in support volume, not complete independence.
Source: MedlinePlus · Teduglutide ↗
Is GLP-2 simply another name for GLP-1?
No. They are different signaling pathways with different therapeutic aims.
References & editorial record
- MedlinePlus · Teduglutide ↗
- Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.